After The Bell
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Amarin Says No FDA Advisory Committee Will Be Scheduled For Its AMR101 NDA

RELATED NEWS
Trade AMRN now with 
2/13/2012 12:49 PM ET

Amarin Corporation plc (AMRN: Quote) said Monday it has been informed by the U.S. Food and Drug Administration that no advisory committee meeting will be scheduled in connection with the FDA's review of the New Drug Application seeking approval for the use AMR101 in the treatment of patients with very high triglycerides, the company's lead product candidate.

The FDA has previously assigned a Prescription Drug User Fee Act date of July 26, 2012 for completion of its review of the AMR101 NDA.

Click here to receive FREE breaking news email alerts for Amarin Corp Plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus